Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,870 | 34,019 | 39,499 | 41,961 | 42,925 |
| Receivables | 34,368 | 32,170 | 29,765 | 26,620 | 39,290 |
| Inventories | 16,243 | 20,493 | 23,872 | 25,532 | 15,691 |
| TOTAL | $113,831 | $100,120 | $112,097 | $112,944 | $118,149 |
| Non-Current Assets | |||||
| PPE Net | 2,200 | 2,533 | 2,895 | 3,265 | 3,629 |
| Intangibles | 59,044 | 68,055 | 77,065 | 86,076 | 95,086 |
| Other Non-Current Assets | 45,595 | 36,434 | 28,139 | 23,192 | 24,839 |
| TOTAL | $106,839 | $107,022 | $108,099 | $112,533 | $123,554 |
| Total Assets | $220,670 | $207,142 | $220,196 | $225,477 | $241,703 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 0 | 0 | 0 | 17,500 |
| Accounts payable and accrued liabilities | 15,180 | 13,494 | 10,107 | 11,882 | 14,635 |
| Accrued Expenses | 63,460 | 52,215 | 53,897 | 53,910 | 67,735 |
| Other current liabilities | 2,274 | N/A | N/A | N/A | N/A |
| TOTAL | $80,914 | $65,709 | $107,300 | $66,487 | $99,870 |
| Non-Current Liabilities | |||||
| Long Term Debt | 38,693 | 38,355 | 38,031 | 30,145 | 17,183 |
| Deferred Revenues | N/A | N/A | 43,296 | 695 | N/A |
| Other Non-Current Liabilities | 150,248 | 153,480 | 102,320 | 112,807 | 111,938 |
| TOTAL | $188,941 | $191,835 | $146,650 | $186,248 | $172,417 |
| Total Liabilities | $269,855 | $257,544 | $253,950 | $252,735 | $272,287 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 236,231 | 218,181 | 210,288 | 209,596 | 209,372 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,678,360 | -1,655,556 | -1,635,517 | -1,626,935 | -1,608,950 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $-49,185 | $-50,402 | $-33,754 | $-27,258 | $-30,584 |
| Total Liabilities And Equity | $220,670 | $207,142 | $220,196 | $225,477 | $241,703 |